JP2023528281A5 - - Google Patents
Info
- Publication number
- JP2023528281A5 JP2023528281A5 JP2022570532A JP2022570532A JP2023528281A5 JP 2023528281 A5 JP2023528281 A5 JP 2023528281A5 JP 2022570532 A JP2022570532 A JP 2022570532A JP 2022570532 A JP2022570532 A JP 2022570532A JP 2023528281 A5 JP2023528281 A5 JP 2023528281A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- pyrazole
- ethyl
- pharmaceutically acceptable
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025139595A JP2025170366A (ja) | 2020-05-22 | 2025-08-25 | 例えばうつ病の治療方法において使用するためのｇｐｒ１３９拮抗薬としての３－（（１ｈ－ピラゾール－４－イル）メチル）－６’－（フェニル）－２ｈ－（１，２’－ビピリジン）－２－オン誘導体および関連化合物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020090111A JP2021183587A (ja) | 2020-05-22 | 2020-05-22 | 複素環化合物 |
| JP2020090111 | 2020-05-22 | ||
| PCT/IB2021/000337 WO2021234451A1 (en) | 2020-05-22 | 2021-05-20 | 3-((1h-pyrazol-4-yl)methyl)-6'-(phenyl)-2h-(1,2'-bipyridin)-2-one derivatives and related compounds as gpr139 antagonists for use in a method of treatment of e.g. depression |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025139595A Division JP2025170366A (ja) | 2020-05-22 | 2025-08-25 | 例えばうつ病の治療方法において使用するためのｇｐｒ１３９拮抗薬としての３－（（１ｈ－ピラゾール－４－イル）メチル）－６’－（フェニル）－２ｈ－（１，２’－ビピリジン）－２－オン誘導体および関連化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023528281A JP2023528281A (ja) | 2023-07-04 |
| JP2023528281A5 true JP2023528281A5 (enExample) | 2024-05-23 |
| JP7734153B2 JP7734153B2 (ja) | 2025-09-04 |
Family
ID=76797026
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020090111A Pending JP2021183587A (ja) | 2020-05-22 | 2020-05-22 | 複素環化合物 |
| JP2022570532A Active JP7734153B2 (ja) | 2020-05-22 | 2021-05-20 | 例えばうつ病の治療方法において使用するためのｇｐｒ１３９拮抗薬としての３－（（１ｈ－ピラゾール－４－イル）メチル）－６’－（フェニル）－２ｈ－（１，２’－ビピリジン）－２－オン誘導体および関連化合物 |
| JP2025139595A Withdrawn JP2025170366A (ja) | 2020-05-22 | 2025-08-25 | 例えばうつ病の治療方法において使用するためのｇｐｒ１３９拮抗薬としての３－（（１ｈ－ピラゾール－４－イル）メチル）－６’－（フェニル）－２ｈ－（１，２’－ビピリジン）－２－オン誘導体および関連化合物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020090111A Pending JP2021183587A (ja) | 2020-05-22 | 2020-05-22 | 複素環化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025139595A Withdrawn JP2025170366A (ja) | 2020-05-22 | 2025-08-25 | 例えばうつ病の治療方法において使用するためのｇｐｒ１３９拮抗薬としての３－（（１ｈ－ピラゾール－４－イル）メチル）－６’－（フェニル）－２ｈ－（１，２’－ビピリジン）－２－オン誘導体および関連化合物 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12590086B2 (enExample) |
| EP (1) | EP4153581B1 (enExample) |
| JP (3) | JP2021183587A (enExample) |
| KR (1) | KR20230015946A (enExample) |
| CN (1) | CN116171276A (enExample) |
| AR (1) | AR122143A1 (enExample) |
| AU (1) | AU2021276623A1 (enExample) |
| BR (1) | BR112022023503A2 (enExample) |
| CA (1) | CA3178798A1 (enExample) |
| IL (1) | IL298275A (enExample) |
| MX (1) | MX2022014576A (enExample) |
| TW (1) | TW202208346A (enExample) |
| WO (1) | WO2021234451A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021183586A (ja) | 2020-05-22 | 2021-12-02 | 武田薬品工業株式会社 | 複素環化合物 |
| JP2021183587A (ja) | 2020-05-22 | 2021-12-02 | 武田薬品工業株式会社 | 複素環化合物 |
| GB202206054D0 (en) * | 2022-04-26 | 2022-06-08 | Cerevance Ltd | Novel Compounds |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1586584A1 (en) | 1996-08-27 | 2005-10-19 | Praecis Pharmaceuticals Incorporated | Modulators of beta-amyloid peptide aggregation comprising D-amino acids |
| DE19736352C1 (de) | 1997-08-21 | 1998-12-10 | Atotech Deutschland Gmbh | Vorrichtung zur Kontaktierung von flachem Behandlungsgut in Durchlaufgalvanisieranlagen |
| EP1194449B1 (en) | 1999-06-28 | 2010-09-22 | Oklahoma Medical Research Foundation | Inhibitors of memapsin 2 and use thereof |
| AP1822A (en) | 2002-02-14 | 2008-01-30 | Pharmacia Corp | Substituted pyridinones as modulators of P38 MAP kinase. |
| US8148367B2 (en) | 2007-01-12 | 2012-04-03 | Takeda Pharmaceutical Company Limited | Renin inhibitors |
| WO2008094556A2 (en) | 2007-01-30 | 2008-08-07 | Biogen Idec Ma Inc. | Imidazolone compounds as tgf-beta family type i receptors, alk5 and/or alk4 antagonists |
| WO2011145735A1 (ja) * | 2010-05-21 | 2011-11-24 | 武田薬品工業株式会社 | チアゾール誘導体 |
| WO2017222952A1 (en) * | 2016-06-23 | 2017-12-28 | Merck Sharp & Dohme Corp. | 3- heteroaryl substituted 5-trifluoromethyl oxadiazoles as histone deacetylase 6 (hdac6) inhibitors |
| AU2019312296B2 (en) * | 2018-07-27 | 2025-05-29 | Arcus Biosciences, Inc. | Pyridone A2R antagonists |
| WO2020097609A1 (en) * | 2018-11-09 | 2020-05-14 | Blackthorn Therapeutics, Inc. | Gpr139 receptor modulators |
| JP2020090111A (ja) | 2018-12-03 | 2020-06-11 | パイオニア株式会社 | 発光システム |
| JP2021183586A (ja) | 2020-05-22 | 2021-12-02 | 武田薬品工業株式会社 | 複素環化合物 |
| JP2021183587A (ja) | 2020-05-22 | 2021-12-02 | 武田薬品工業株式会社 | 複素環化合物 |
-
2020
- 2020-05-22 JP JP2020090111A patent/JP2021183587A/ja active Pending
-
2021
- 2021-05-20 US US17/999,514 patent/US12590086B2/en active Active
- 2021-05-20 EP EP21737769.6A patent/EP4153581B1/en active Active
- 2021-05-20 KR KR1020227044430A patent/KR20230015946A/ko active Pending
- 2021-05-20 IL IL298275A patent/IL298275A/en unknown
- 2021-05-20 AR ARP210101387A patent/AR122143A1/es unknown
- 2021-05-20 CA CA3178798A patent/CA3178798A1/en active Pending
- 2021-05-20 AU AU2021276623A patent/AU2021276623A1/en active Pending
- 2021-05-20 WO PCT/IB2021/000337 patent/WO2021234451A1/en not_active Ceased
- 2021-05-20 BR BR112022023503A patent/BR112022023503A2/pt unknown
- 2021-05-20 CN CN202180059093.3A patent/CN116171276A/zh active Pending
- 2021-05-20 JP JP2022570532A patent/JP7734153B2/ja active Active
- 2021-05-20 TW TW110118337A patent/TW202208346A/zh unknown
- 2021-05-20 MX MX2022014576A patent/MX2022014576A/es unknown
-
2025
- 2025-08-25 JP JP2025139595A patent/JP2025170366A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8569294B2 (en) | 2-(cyclic amino)-pyrimidone derivatives | |
| JP2020033357A5 (enExample) | ||
| AU2014291711B2 (en) | Autotaxin inhibitors comprising a heteroaromatic ring-benzyl-amide-cycle core | |
| JP6117430B2 (ja) | 選択的ヒストン脱アセチル化酵素抑制剤としての新規化合物およびこれを含む薬剤学的組成物 | |
| JP2008513514A5 (enExample) | ||
| AU2005260821B2 (en) | Fused benzamide compound and vanilloid receptor 1 (VR1) activity inhibitor | |
| US20100292266A1 (en) | Oxazolyl Piperidine Modulators of Fatty Acid Amide Hydrolase | |
| JPWO2020017587A5 (enExample) | ||
| JP5792173B2 (ja) | ｍＧｌｕＲ５ネガティブアロステリックモジュレータとしての置換ヘテロアリールアミド類似体、ならびに、その形成方法および使用方法 | |
| JP2007510689A5 (enExample) | ||
| JP2013539777A5 (enExample) | ||
| TWI471322B (zh) | 新穎醯胺衍生物及其作為醫藥之用途 | |
| JP2008513515A5 (enExample) | ||
| TW201333012A (zh) | 咪唑并吡咯啶酮化合物 | |
| AU2005238296A1 (en) | Substituted morpholine compounds for the treatment of central nervous system disorders | |
| US20160060222A1 (en) | Amino-quinolines as kinase inhibitors | |
| CN102971291B (zh) | 新型酰胺衍生物及其作为药物的用途 | |
| AU2006239418A1 (en) | Novel oxadiazole derivatives and their medical use | |
| JP2007505878A5 (enExample) | ||
| JP2003063994A (ja) | アルツハイマー病およびパーキンソン病に関連する痴呆または認識障害のための組合せ治療 | |
| TWI434690B (zh) | 雜雙環衍生物 | |
| HRP20161797T1 (hr) | Spojevi 1,3-oksazolidina ili 1,3-oksazinana kao antagonisti receptora oreksina | |
| JP2015524483A5 (enExample) | ||
| AU2008257154B2 (en) | Tetracyclic inhibitors of fatty acid amide hydrolase | |
| JP2023528280A5 (enExample) |